Gefitinib medicinal composition and tablet containing gefitinib medicinal composition

Abstract

The invention belongs to the field of medicinal preparations, and provides a gefitinib medicinal composition and a tablet thereof. The gefitinib medicinal composition contains polyacrylic resin substances. By adopting the provided composition and tablet, the precipitating speed of gefitinib from a solution can be well controlled, and the bioavailability of gefitinib is improved.

Description

[0001] technical field [0002] The invention belongs to the field of pharmaceutical preparations, in particular to a gefitinib pharmaceutical composition and a tablet containing the gefitinib pharmaceutical composition. [0003] Background technique [0004] Gefitinib was first disclosed in the international patent application WO96 / 33980, and its chemical name is N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholine-4-propoxy Base) quinazoline-4-amine, the structure is shown in the following formula: [0005] . [0006] Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by AstraZeneca. In August 2002, Japan first approved gefitinib tablets (Iressa, Iressa). ) as a drug for the treatment of non-small cell lung cancer. In February 2005, the State Food and Drug Administration approved gefitinib tablets for the treatment of locally advanced or metastatic non-small cell lung cancer who had previously received chemotherapy....

AI Technical Summary

Problems solved by technology

However, generally low-viscosity HPMC is used as a film coating material, and its dosage is limited. In this patent, the dosage of HPMC in the coated tablet is about 8 mg, and the effect of inhibiting drug precipitation is very limited; while high-viscosity HPMC has slow control Release effect, excessive weight gain of the coating will prevent the release of the drug in the immediate release drug formulation

Images